Poll: Type 2 Diabetes Medications
There are many therapeutic options in type 2 diabetes.
Linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk for a composite cardiovascular or renal outcome over a median 2.2 years.
High circulating total prolactin concentrations may be linked with a lower risk for type 2 diabetes in women.
Dapagliflozin was not associated with either a higher or lower rate of MACE compared with placebo in patients with type 2 diabetes who had or were at risk for atherosclerotic ...